[go: up one dir, main page]

MX2025008755A - 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression - Google Patents

5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression

Info

Publication number
MX2025008755A
MX2025008755A MX2025008755A MX2025008755A MX2025008755A MX 2025008755 A MX2025008755 A MX 2025008755A MX 2025008755 A MX2025008755 A MX 2025008755A MX 2025008755 A MX2025008755 A MX 2025008755A MX 2025008755 A MX2025008755 A MX 2025008755A
Authority
MX
Mexico
Prior art keywords
dimethyltryptamine
methoxy
treatment
postpartum depression
postpartum
Prior art date
Application number
MX2025008755A
Other languages
Spanish (es)
Inventor
Theis Terwey
Conor Burke
Naoise Gaffney
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2023/057883 external-priority patent/WO2023186835A1/en
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of MX2025008755A publication Critical patent/MX2025008755A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD).
MX2025008755A 2023-01-30 2025-07-25 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression MX2025008755A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP23153995 2023-01-30
EP23153939 2023-01-30
PCT/EP2023/057883 WO2023186835A1 (en) 2022-03-27 2023-03-27 Treatment of mental disorders
PCT/EP2023/057873 WO2023186826A1 (en) 2022-03-27 2023-03-27 5-meo-dmt for use in the treatment of postpartum depression
PCT/EP2023/076817 WO2024160390A1 (en) 2023-01-30 2023-09-27 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression

Publications (1)

Publication Number Publication Date
MX2025008755A true MX2025008755A (en) 2025-11-03

Family

ID=88206855

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2025008755A MX2025008755A (en) 2023-01-30 2025-07-25 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
MX2025008728A MX2025008728A (en) 2023-01-30 2025-07-25 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025008728A MX2025008728A (en) 2023-01-30 2025-07-25 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers

Country Status (7)

Country Link
EP (2) EP4658265A1 (en)
KR (2) KR20250135903A (en)
CN (2) CN120813348A (en)
AU (2) AU2023426967A1 (en)
IL (2) IL322428A (en)
MX (2) MX2025008755A (en)
WO (2) WO2024160389A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (en) 1998-01-29 1999-10-14 Markus Storz Inhaler for generating vapors containing aroma and / or active substances from plant material and / or liquids
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
EP1625335A2 (en) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
DE502006008441D1 (en) 2006-08-01 2011-01-13 Stobi Gmbh & Co Kg Valve balloon for inhalers
EP4353314A3 (en) 2019-02-22 2024-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
PL3927338T3 (en) * 2019-02-22 2025-03-03 GH Research Ireland Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
US11406619B2 (en) * 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations

Also Published As

Publication number Publication date
AU2023426967A1 (en) 2025-09-18
AU2023427437A1 (en) 2025-09-18
IL322428A (en) 2025-09-01
CN120813348A (en) 2025-10-17
EP4658265A1 (en) 2025-12-10
WO2024160390A1 (en) 2024-08-08
EP4658266A1 (en) 2025-12-10
WO2024160389A1 (en) 2024-08-08
CN120712084A (en) 2025-09-26
KR20250139377A (en) 2025-09-23
KR20250135903A (en) 2025-09-15
MX2025008728A (en) 2025-10-01
IL322429A (en) 2025-09-01

Similar Documents

Publication Publication Date Title
MX2025008755A (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
FI4349407T3 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2020014000A (en) Film formulations containing dexmedetomidine and methods of producing them.
MX2022016498A (en) Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer.
MX2024003952A (en) Combination comprising atogepant for treating migraine.
MX2023001071A (en) Treatment of migraine.
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
MX2024005107A (en) Novel use of quinazolinone compound for the treatment of cancer.
NZ799504A (en) Use of penehyclidine in treatment or prevention of vision-impairing eye diseases
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
MX2022012310A (en) Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase.
MXPA04003548A (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi).
WO2023046060A8 (en) Treatment of cancer patients having kras mutations
NZ751972A (en) Treatment of prurigo nodularis
MX2015009546A (en) Increased dosage of efavirenz for the treatment of cancer.
ZA202407245B (en) Novel use of pitolisant for treating severe fatigue
MX2024010644A (en) Use of iptacopan for the treatment of lupus nephritis.
ZA202305122B (en) Prophylaxis and treatment of angioedema
TW200616644A (en) Medicine for prevention or treatment of diabetes
MX2025008750A (en) 5-meo-dmt for use in the treatment of postpartum depression
MX2025006240A (en) Pharmaceutical composition for prevention or treatment of drug-related peptic ulcer comprising zastaprazan or pharmaceutically acceptable salt thereof
MX2025005021A (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2025000673A (en) Methods of administering nalbuphine
MX2022011651A (en) Method for treating diabetes.